-
Sector Analysis
NewFinland Cards and Payments – Opportunities and Risks to 2028
Finland Cards and Payments Market Report Overview The annual value of card transactions in the Finland cards and payments market was $72.9 billion in 2023. The value is expected to grow at a CAGR of more than 4% during 2024-2028. Finland has a matured digital payments market facilitated by widespread familiarity with electronic payments, a highly banked population, and a well-established payment infrastructure. Finland Card Transactions Outlook, 2024-2028 ($ Billion) Buy the Full Report for More Information on the Finland...
-
Sector Analysis
NewKuwait Cards and Payments – Opportunities and Risks to 2028
Kuwait Cards and Payments Market Report Overview The annual value of card transactions in the Kuwait cards and payments market was $126.6 billion in 2023 and the value will grow at a CAGR of more than 6% during 2024-2028. Kuwait’s payment card market is growing, driven by the combined efforts of the government and financial institutions to promote electronic payments. In addition, a developing and expanding payment acceptance infrastructure has encouraged consumers to use electronic payments for day-to-day transactions. Kuwait...
-
Sector Analysis
NewSlovenia Cards and Payments – Opportunities and Risks to 2028
Slovenia Cards and Payments Market Report Overview The annual value of card transactions in the Slovenia cards and payments market was $12.2 billion in 2023 and the value will grow at a CAGR of more than 8% during 2024-2028. The country’s payments market is considered fast-developing because of the consistent surge in technological innovations and the launch of new banking and payment services. This is supported by government initiatives to improve banking penetration, increasing financial knowledge among citizens, and efforts...
-
Product Insights
NewLikelihood of Approval Analysis for Neuroendocrine Tumors
Overview How likely is it that the drugs in Neuroendocrine Tumors will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neuroendocrine Tumors Overview Neuroendocrine tumor begins in the hormone-producing cells of the...
-
Product Insights
NewLikelihood of Approval Analysis for Hypereosinophilic Syndrome
Overview How likely is it that the drugs in Hypereosinophilic Syndrome will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hypereosinophilic Syndrome Overview Hypereosinophilic syndrome (HES) is a disease characterized by a...
-
Product Insights
NewLikelihood of Approval Analysis for Retinopathy
Overview How likely is it that the drugs in Retinopathy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retinopathy Overview Retinopathy is any damage to the retina of the eyes, which...
-
Product Insights
NewLikelihood of Approval Analysis for Tuberculosis
Overview How likely is it that the drugs in Tuberculosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tuberculosis Overview Tuberculosis, commonly known as TB, is a bacterial infection that can...
-
Product Insights
NewLikelihood of Approval Analysis for Benign Tumor
Overview How likely is it that the drugs in Benign Tumor will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Benign Tumor Overview A benign Tumor is also known as non-cancerous. It...
-
Product Insights
NewLikelihood of Approval Analysis for Bone Sarcoma
Overview How likely is it that the drugs in Bone Sarcoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bone Sarcoma Overview Bone sarcoma also known as bone cancer or primary...
-
Product Insights
NewLikelihood of Approval Analysis for Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome)
Overview How likely is it that the drugs in Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atypical Hemolytic Uremic Syndrome...